Artiva Biotherapeutics Q2 FY26 net loss widens to $25.01 million; R&D expenses rise to $21.93 million

Reuters2026/08/06 20:23

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

Artiva Biotherapeutics posted a Q2 net loss of USD 25.01 million, widening from USD 21.25 million a year earlier.
RD spending rose to USD 21.93 million from USD 17.86 million, while GA was little changed at USD 4.97 million.
Cash, cash equivalents and investments climbed to USD 349.39 million at June 30 from USD 108.01 million at Dec. 31, 2025.
FDA granted RMAT designation for AlloNK with rituximab in refractory rheumatoid arthritis; Phase 3 start planned in H2 2026 in about 150 patients.
CEO Fred Aslan said EULAR data reinforced AlloNK’s potential for deep B-cell depletion with tolerability supportive of outpatient administration.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Artiva Biotherapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202608061605PRIMZONEFULLFEED9805015) on August 06, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

Artiva Biotherapeutics Q2 FY26 net loss widens to $25.01 million; R&D expenses rise to $21.93 million

You may also like

Crypto prices